We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ADCETRIS (Takeda Pharmaceuticals Australia Pty Ltd)
Product name
ADCETRIS
Date registered
Evaluation commenced
Decision date
Approval time
146 working days (255)
Active ingredients
brentuximab vedotin
Registration type
EOI
Indication
Peripheral T-cell lymphoma
ADCETRIS (powder for injection) is now also indicated for the treatment of adult patients with previously untreated CD30+ peripheral T-cell lymphoma (PTCL) in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) (see 5.1 Pharmacodynamic Propertues, Clinical Trials).